Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00117676




Registration number
NCT00117676
Ethics application status
Date submitted
30/06/2005
Date registered
8/07/2005
Date last updated
7/03/2017

Titles & IDs
Public title
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
Scientific title
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B
Secondary ID [1] 0 0
2004-005119-27
Secondary ID [2] 0 0
GS-US-174-0102
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TDF
Treatment: Drugs - ADV
Treatment: Drugs - TDF placebo
Treatment: Drugs - ADV placebo
Treatment: Drugs - FTC/TDF

Experimental: TDF-TDF - TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.

Active comparator: ADV-TDF - ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.


Treatment: Drugs: TDF
300 mg tablet administered orally once daily

Treatment: Drugs: ADV
10 mg tablet administered orally once daily

Treatment: Drugs: TDF placebo
Tablet administered orally once daily

Treatment: Drugs: ADV placebo
Tablet administered orally once daily

Treatment: Drugs: FTC/TDF
200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48
Timepoint [1] 0 0
Baseline; Week 48
Secondary outcome [1] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48
Timepoint [1] 0 0
Week 48
Secondary outcome [2] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96
Timepoint [2] 0 0
Week 96
Secondary outcome [3] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384
Timepoint [3] 0 0
Weeks 144, 192, 240, 288, 336, and 384
Secondary outcome [4] 0 0
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 432 and 480
Timepoint [4] 0 0
Weeks 432 and 480
Secondary outcome [5] 0 0
Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Timepoint [5] 0 0
Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [6] 0 0
Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Timepoint [6] 0 0
Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [7] 0 0
Percentage of Participants With Histological Response at Week 48
Timepoint [7] 0 0
Baseline; Week 48
Secondary outcome [8] 0 0
Percentage of Participants With Histological Response at Week 240
Timepoint [8] 0 0
Baseline; Week 240
Secondary outcome [9] 0 0
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48
Timepoint [9] 0 0
Baseline; Week 48
Secondary outcome [10] 0 0
Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240
Timepoint [10] 0 0
Baseline; Week 240
Secondary outcome [11] 0 0
Ranked Assessment of Necroinflammation and Fibrosis at Week 48
Timepoint [11] 0 0
Baseline; Week 48
Secondary outcome [12] 0 0
Ranked Assessment of Necroinflammation and Fibrosis at Week 240
Timepoint [12] 0 0
Baseline; Week 240
Secondary outcome [13] 0 0
Percentage of Participants With ALT Normalization at Week 48
Timepoint [13] 0 0
Baseline; Week 48
Secondary outcome [14] 0 0
Percentage of Participants With ALT Normalization at Weeks 96
Timepoint [14] 0 0
Baseline; Week 96
Secondary outcome [15] 0 0
Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384
Timepoint [15] 0 0
Baseline; Weeks 144, 192, 240, 288, 336, and 384
Secondary outcome [16] 0 0
Percentage of Participants With ALT Normalization at Weeks 432 and 480
Timepoint [16] 0 0
Baseline; Weeks 432 and 480
Secondary outcome [17] 0 0
Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Timepoint [17] 0 0
Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [18] 0 0
Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Timepoint [18] 0 0
Week 48; Weeks 96, 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [19] 0 0
Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48
Timepoint [19] 0 0
Baseline; Week 48
Secondary outcome [20] 0 0
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96
Timepoint [20] 0 0
Baseline; Week 96
Secondary outcome [21] 0 0
Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, 384, 432, and 480
Timepoint [21] 0 0
Baseline; Weeks 144, 192, 240, 288, 336, 384, 432, and 480
Secondary outcome [22] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)
Timepoint [22] 0 0
Baseline; Week 48
Secondary outcome [23] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)
Timepoint [23] 0 0
Baseline; Weeks 49 to 96
Secondary outcome [24] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)
Timepoint [24] 0 0
Baseline; Weeks 97 to 144
Secondary outcome [25] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)
Timepoint [25] 0 0
Baseline; Weeks 145 to 192
Secondary outcome [26] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)
Timepoint [26] 0 0
Baseline; Weeks 193 to 240
Secondary outcome [27] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)
Timepoint [27] 0 0
Baseline; Weeks 241 to 288
Secondary outcome [28] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)
Timepoint [28] 0 0
Baseline; Weeks 289 to 336
Secondary outcome [29] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)
Timepoint [29] 0 0
Baseline; Weeks 337 to 384
Secondary outcome [30] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 432 (Resistance Surveillance)
Timepoint [30] 0 0
Baseline; Weeks 385 to 432
Secondary outcome [31] 0 0
Number of Participants With HBV Genotypic Changes From Baseline at Week 480 (Resistance Surveillance)
Timepoint [31] 0 0
Baseline; Weeks 433 to 480

Eligibility
Key inclusion criteria
Key

* Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for at least 6 months.
* 18 through 69 years of age, inclusive.
* Active hepatitis B e-antigen (HBeAg) negative chronic HBV infection, with all of the following:

* HBeAg negative and HBeAb positive at screening
* Alanine aminotransferase (ALT) levels > the upper limit of the normal range (ULN) and = 10 x ULN
* Serum HBV DNA > 100,000 copies/mL at screening
* Creatinine clearance = 70 mL/min
* Hemoglobin = 8 g/dL
* Neutrophils = 1,000 /mL
* Knodell necroinflammatory score = 3 and a Knodell fibrosis score < 4; however, up to 120 patients with cirrhosis, ie, a Knodell fibrosis score equal to 4, will be eligible for enrollment
* Negative serum ß-human chorionic gonadotropin (hCG)
* Nucleotide naive, ie, no prior nucleotide (TDF or ADV) therapy for greater than 12 weeks
* Nucleoside naive, ie, no prior nucleoside (any nucleoside) therapy for greater than 12 weeks. However, up to 120 patients with > 12 weeks prior lamivudine experience will be eligible
* Willing and able to provide written informed consent
* Had a liver biopsy performed within 6 months of baseline and has readable biopsy slides or agrees to have a biopsy performed prior to baseline

Key
Minimum age
18 Years
Maximum age
69 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant women, women who are breast feeding, or women who believe they may wish to become pregnant during the course of the study
* Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study.
* Decompensated liver disease defined as conjugated bilirubin > 1.5 x ULN, prothrombin time (PT) > 1.5 x ULN, platelets < 75,000/mL, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
* Received any nucleoside, nucleotide (TDF or ADV) or interferon (pegylated or not) therapy within 6 months prior to the pre treatment biopsy
* Evidence of hepatocellular carcinoma (HCC)
* Coinfection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis D virus (HDV)
* Significant renal, cardiovascular, pulmonary, or neurological disease
* Received solid organ or bone marrow transplantation
* Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
* Has proximal tubulopathy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2016
Sample size
Target
Accrual to date
Final
382
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Concord
Recruitment hospital [3] 0 0
- Westmead
Recruitment hospital [4] 0 0
- Woolloongabba
Recruitment hospital [5] 0 0
- Clayton
Recruitment hospital [6] 0 0
- Fitzroy
Recruitment hospital [7] 0 0
- Heidelberg
Recruitment hospital [8] 0 0
- Prahan
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
40102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3084 - Heidelberg
Recruitment postcode(s) [8] 0 0
3004 - Prahan
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Hawaii
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
Bulgaria
State/province [9] 0 0
Sofia
Country [10] 0 0
Bulgaria
State/province [10] 0 0
Varna
Country [11] 0 0
Canada
State/province [11] 0 0
Alberta
Country [12] 0 0
Canada
State/province [12] 0 0
British Columbia
Country [13] 0 0
Canada
State/province [13] 0 0
Manitoba
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Czech Republic
State/province [15] 0 0
Brno
Country [16] 0 0
Czech Republic
State/province [16] 0 0
Hradec Kralove
Country [17] 0 0
Czech Republic
State/province [17] 0 0
Praha 4
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Praha 6 - Stresovice
Country [19] 0 0
France
State/province [19] 0 0
Clichy
Country [20] 0 0
France
State/province [20] 0 0
Creteil
Country [21] 0 0
France
State/province [21] 0 0
Lille
Country [22] 0 0
France
State/province [22] 0 0
Lyon
Country [23] 0 0
France
State/province [23] 0 0
Nancy
Country [24] 0 0
France
State/province [24] 0 0
Paris
Country [25] 0 0
France
State/province [25] 0 0
Strasbourg
Country [26] 0 0
France
State/province [26] 0 0
Toulouse
Country [27] 0 0
Germany
State/province [27] 0 0
Duesseldorf
Country [28] 0 0
Germany
State/province [28] 0 0
Frankfurt
Country [29] 0 0
Germany
State/province [29] 0 0
Hamburg
Country [30] 0 0
Germany
State/province [30] 0 0
Hannover
Country [31] 0 0
Germany
State/province [31] 0 0
Herne
Country [32] 0 0
Germany
State/province [32] 0 0
Homburg/Saar
Country [33] 0 0
Germany
State/province [33] 0 0
Mainz
Country [34] 0 0
Germany
State/province [34] 0 0
Munchen
Country [35] 0 0
Germany
State/province [35] 0 0
Tubingen
Country [36] 0 0
Greece
State/province [36] 0 0
Athens
Country [37] 0 0
Greece
State/province [37] 0 0
Larissa
Country [38] 0 0
Greece
State/province [38] 0 0
Leipzig
Country [39] 0 0
Greece
State/province [39] 0 0
Thessaloniki
Country [40] 0 0
Italy
State/province [40] 0 0
Bologna
Country [41] 0 0
Italy
State/province [41] 0 0
Torino
Country [42] 0 0
Netherlands
State/province [42] 0 0
Rotterdam
Country [43] 0 0
New Zealand
State/province [43] 0 0
Auckland
Country [44] 0 0
New Zealand
State/province [44] 0 0
Hamilton
Country [45] 0 0
New Zealand
State/province [45] 0 0
Whakatane
Country [46] 0 0
Poland
State/province [46] 0 0
Bialystok
Country [47] 0 0
Poland
State/province [47] 0 0
Bydgoszcz
Country [48] 0 0
Poland
State/province [48] 0 0
Chorzow
Country [49] 0 0
Poland
State/province [49] 0 0
Krakow
Country [50] 0 0
Poland
State/province [50] 0 0
Warszawa
Country [51] 0 0
Poland
State/province [51] 0 0
Wroclaw
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Spain
State/province [53] 0 0
Barcelona
Country [54] 0 0
Spain
State/province [54] 0 0
Valencia
Country [55] 0 0
Turkey
State/province [55] 0 0
Bursa
Country [56] 0 0
Turkey
State/province [56] 0 0
Istanbul
Country [57] 0 0
Turkey
State/province [57] 0 0
Izmir
Country [58] 0 0
United Kingdom
State/province [58] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of pre-core mutant chronic hepatitis B. Participants will receive TDF or ADV for 48 weeks (double-blind). After 48 weeks, eligible participants switched to open-label TDF for up to 480 weeks.
Trial website
https://clinicaltrials.gov/study/NCT00117676
Trial related presentations / publications
Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014 Feb;59(2):434-42. doi: 10.1002/hep.26686.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013 Aug;58(2):505-13. doi: 10.1002/hep.26277. Epub 2013 May 3.
Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015 Jan;60(1):260-8. doi: 10.1007/s10620-014-3336-7. Epub 2014 Sep 2.
Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (>/= 9 log10 copies/ml). Liver Int. 2015 Feb;35(2):422-8. doi: 10.1111/liv.12694. Epub 2014 Oct 28.
Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.
Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015 May;60(5):1457-64. doi: 10.1007/s10620-014-3486-7. Epub 2014 Dec 23.
Corsa A, Liu Y, Flaherty JF, Marcellin P, Miller M, Kitrinos KM. No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment [Abstract 1707]. The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD); 2014 08-10 November; Boston MA.
Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials [Abstract]. 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 November 7-11; Boston, MA.
Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, et al. Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis [Poster Number 1429]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 November 4-8; San Francisco, California.
Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017 Jan;24(1):68-74. doi: 10.1111/jvh.12613. Epub 2016 Sep 23.
Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10.
Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.
Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1087-1094.e2. doi: 10.1016/j.cgh.2017.01.032. Epub 2017 Feb 12.
Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.
Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00117676